Literature DB >> 24040451

Immunochemiluminescent detection of galectin-3 in tumoral tissue from prostate.

Jorge Luiz Araújo-Filho1, Mário Ribeiro Melo-Junior, Eduardo Isidoro Carneiro Beltrão, Luiza Rayanna Amorim de Lima, Consuelo Barreto Lins Antunes, Luiz Bezerra de Carvalho.   

Abstract

This work proposes a chemiluminescent quantitative method for galectin-3 (Gal3) detection in prostate tissues. Monoclonal antibody anti-Gal3 was conjugated to acridinium ester (AE) and the complex formed with Gal3 in the prostate tissue was chemiluminescently detected. The light emission (expressed in Relative Light Unit-RLU) showed mean values higher for benign prostatic hyperplasia than normal tissues and adenocarcinoma. These differences showed to be statistically significant (p < 0.001). There was a linear relationship between RLU and tissue area. Furthermore, these values were dramatically reduced when the tissue samples were previously incubated with non labeled anti-Gal3. Finally, the anti-Gal3-AE solution in buffer stored at 4°C and the treated samples showed to be stable during a year and at least 72 h, respectively. Gal3 content in prostate tissue was higher in benign prostatic hyperplasia than normal tissues and much lower in adenocarcinoma. This quantitative, specific and sensitive method based on labeling antibody to acridinium ester can be applied to detect antigen in tissue.

Entities:  

Keywords:  Chemiluminescence; galectin-3; immunohistochemistry; prostate tissue

Mesh:

Substances:

Year:  2013        PMID: 24040451      PMCID: PMC3759493     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

Review 1.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

2.  Human galectin-3 (Mac-2 antigen): defining molecular switches of affinity to natural glycoproteins, structural and dynamic aspects of glycan binding by flexible ligand docking and putative regulatory sequences in the proximal promoter region.

Authors:  Mickaël Krzeminski; Tanuja Singh; Sabine André; Martin Lensch; Albert M Wu; Alexandre M J J Bonvin; Hans-Joachim Gabius
Journal:  Biochim Biophys Acta       Date:  2010-11-08

3.  Immunoassays using acridinium esters.

Authors:  I Weeks; M Sturgess; R C Brown; J S Woodhead
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

Review 5.  Histologic grading of prostate cancer: a perspective.

Authors:  D F Gleason
Journal:  Hum Pathol       Date:  1992-03       Impact factor: 3.466

6.  Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression.

Authors:  F A van den Brûle; D Waltregny; F T Liu; V Castronovo
Journal:  Int J Cancer       Date:  2000-07-20       Impact factor: 7.396

7.  Circulating galectin-3 in the bloodstream: An emerging promoter of cancer metastasis.

Authors:  Lu-Gang Yu
Journal:  World J Gastrointest Oncol       Date:  2010-04-15

8.  Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model.

Authors:  Kimberley A Stannard; Patrick M Collins; Koichi Ito; Emily M Sullivan; Stacy A Scott; Elwyn Gabutero; I Darren Grice; Pauline Low; Ulf J Nilsson; Hakon Leffler; Helen Blanchard; Stephen J Ralph
Journal:  Cancer Lett       Date:  2010-09-09       Impact factor: 8.679

9.  Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3.

Authors:  Stéphane Califice; Vincent Castronovo; Marc Bracke; Frédéric van den Brûle
Journal:  Oncogene       Date:  2004-09-30       Impact factor: 9.867

10.  Immobilization of anti-galectin-3 onto polysiloxane-polyvinyl alcohol disks for tumor prostatic diseases diagnosis.

Authors:  Mario Ribeiro de Melo-Júnior; Jorge Luiz Silva Araújo-Filho; Consuelo Antunes Barreto Lins; Nicodemos Teles de Pontes-Filho; Luiz Bezerra de Carvalho
Journal:  Appl Biochem Biotechnol       Date:  2009-09-02       Impact factor: 2.926

View more
  1 in total

Review 1.  Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).

Authors:  Rui Dong; Min Zhang; Qunying Hu; Shan Zheng; Andrew Soh; Yijie Zheng; Hui Yuan
Journal:  Int J Mol Med       Date:  2017-12-05       Impact factor: 4.101

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.